Global market data

Cryptocurrencies: 6,286
Markets: 574
Marketcap: $ 1.48 T
24h Vol: $ 229.82 B
BTC Dominance: 59.66%

Gilead Sciences, Inc. (GILD) Stock Price, Quote & News

GILD
Gilead Sciences, Inc.
GILD
$61.40
2.21%

Notice: Undefined index: symbol in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 362

Notice: Undefined index: symbol in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 362

Notice: Undefined index: symbol in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 365

Notice: Undefined index: company_name in /home/u908330461/domains/liquidary.com/public_html/wp-content/plugins/massive-stock-widgets/includes/api.php on line 365

Stock Screener

Gilead Sciences, Inc.

EQUITY

type

Healthcare

sector

11.80K

#employees

333 Lakeside Drive
94404, Foster City, CA

United States

address

Gilead Sciences, Inc.
Status: Active
Sector: Healthcare
Industry: Drug Manufacturersโ€”General
Employees: 11800
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Phone650-574-3000
Websitehttp://www.gilead.com
y8
ad

Gilead Sciences, Inc.โ€‹ |

Stock Market Data
Gilead Sciences, Inc.โ€‹

Market Data

Open

$62.78 

Close vs last close

$62.79 vs $62.79

High

$62.79

Low

$61.39

Price

$61.40

Market Cap

$76.97B

24h volume

9.83M

# shares

1.25B

24h Change

$1.39

24h Change (%)

-2.21

52W high

$85.97

52w LOW

$56.56

Dividend yield

4.3318998

Dividend rate

2.72

eps

0.098

Subscribe To Our Newsletter ๐Ÿ“ฌ

Subscribe To Our Newsletter ๐Ÿ“ฌ

ย 

Join the Liquidary Newsletter to stay up to date on recent movements in markets, insights and educational content. We will occasionally reach out to you with original content and updates on Liquidary.

ย 

You have Successfully Subscribed!